Decision Resources, Inc., announces the publication of Ovarian Cancer, a new study that evaluates the commercial potential of novel agents to treat this indication. This study presents data on investigational therapies in early- and late-stage development and offers critical strategic analysis to help companies competing in this market to position their products.
Many ovarian cancer drugs are in late-stage development and will become available for use in a larger number of treatment-refractory or drug-resistant patients within the next five years. Drugs that are evaluated in this study include new-generation analogues of currently marketed classes, members of novel classes (angiogenesis inhibitors, inhibitors of drug-resistance processes, vaccines, and immunotherapies), and agents that are marketed for other cancers that are also undergoing trials in ovarian cancer. We find that monoclonal antibodies constitute a particularly dynamic field of development.
Monoclonal Antibodies Are Poised to Have a Significant Impact on the Ovarian Cancer Market
Within the next five years, monoclonal antibodies in late-stage development programs will become available for use in ovarian cancer. Trastuzumab (Genentech/Roche's Herceptin), already approved for metastatic breast cancer that overexpresses the oncogene HER2, will have a major impact on the ovarian cancer market, reaching sales of almost $90 million by 2010. One of the reasons for this impressive figure is that a 35-week course of trastuzumab cost nearly $30,000 in 2000, and physicians estimate the average duration of trastuzumab therapy to be 6-18 months.
Clinical Data Indicate That Theragyn Improves Survival Times in Ovarian Cancer
Pemtumomab (Antisoma/Abbott Laboratories' Theragyn) is in Phase III trials in the United States and Europe for the adjuvant treatment of ovarian cancer. Pemtumomab is likely to be introduced into the ovarian cancer market by 2005, and if results of Phase III trials replicate the positive findings of earlier investigations, it will have significant commercial potential, also reaching sales of almost $90 million by 2010 for the treatment of ovarian cancer only.
Ovarian Cancer offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this disease. This study is part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or firstname.lastname@example.org. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or email@example.com. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama, +1-781-296-2553, email@example.com